AnteoTech Limited (ADO.AX)
AUD 0.02
(0.0%)
AUD 0.02
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -8.88 Million AUD | 29.82% |
| 2023 | -12.65 Million AUD | -18.08% |
| 2022 | -10.71 Million AUD | -72.42% |
| 2021 | -6.21 Million AUD | -98.8% |
| 2020 | -3.12 Million AUD | 5.16% |
| 2019 | -3.29 Million AUD | 2.62% |
| 2018 | -3.38 Million AUD | 51.68% |
| 2017 | -7 Million AUD | -1.31% |
| 2016 | -6.91 Million AUD | -62.57% |
| 2015 | -4.25 Million AUD | -70.67% |
| 2014 | -2.49 Million AUD | -14.36% |
| 2013 | -2.17 Million AUD | 8.44% |
| 2012 | -2.38 Million AUD | -7.1% |
| 2011 | -2.22 Million AUD | 0.79% |
| 2010 | -2.24 Million AUD | -14.93% |
| 2009 | -1.94 Million AUD | -10.61% |
| 2008 | -1.76 Million AUD | -12.72% |
| 2007 | -1.56 Million AUD | 74.96% |
| 2006 | -6.24 Million AUD | -295.38% |
| 2005 | -1.57 Million AUD | 0.0% |
| 2004 | - AUD | 100.0% |
| 2003 | -2.94 Million AUD | 67.85% |
| 2002 | -9.16 Million AUD | -554.1% |
| 2001 | -1.4 Million AUD | -156.59% |
| 2000 | -546 Thousand AUD | -26877.83% |
| 1999 | 2039.00 AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -6.52 Million AUD | 0.0% |
| 2024 FY | -8.88 Million AUD | 29.82% |
| 2024 Q2 | -2.35 Million AUD | 0.0% |
| 2023 Q2 | -3.54 Million AUD | 0.0% |
| 2023 FY | -12.65 Million AUD | -18.08% |
| 2023 Q4 | -9.1 Million AUD | 0.0% |
| 2022 FY | -10.71 Million AUD | -72.42% |
| 2022 Q4 | -6.89 Million AUD | 0.0% |
| 2022 Q2 | -3.82 Million AUD | 0.0% |
| 2021 FY | -6.21 Million AUD | -98.8% |
| 2021 Q2 | -1.46 Million AUD | 0.0% |
| 2021 Q4 | -4.74 Million AUD | 0.0% |
| 2020 Q4 | -2.01 Million AUD | 0.0% |
| 2020 FY | -3.12 Million AUD | 5.16% |
| 2020 Q2 | -1.1 Million AUD | 0.0% |
| 2019 FY | -3.29 Million AUD | 2.62% |
| 2019 Q2 | -1.6 Million AUD | 0.0% |
| 2019 Q4 | -1.69 Million AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 Q2 | -2.79 Million AUD | 0.0% |
| 2018 FY | -3.38 Million AUD | 51.68% |
| 2017 Q4 | - AUD | 0.0% |
| 2017 FY | -7 Million AUD | -1.31% |
| 2017 Q2 | -5.21 Million AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2016 Q2 | -3.01 Million AUD | 0.0% |
| 2016 FY | -6.91 Million AUD | -62.57% |
| 2015 FY | -4.25 Million AUD | -70.67% |
| 2015 Q4 | -1.98 Million AUD | 0.0% |
| 2015 Q2 | -2.26 Million AUD | 0.0% |
| 2014 Q2 | -620.45 Thousand AUD | 0.0% |
| 2014 Q4 | -1.87 Million AUD | 0.0% |
| 2014 FY | -2.49 Million AUD | -14.36% |
| 2013 Q2 | -736.32 Thousand AUD | -23.74% |
| 2013 Q1 | -595.04 Thousand AUD | 0.0% |
| 2013 FY | -2.17 Million AUD | 8.44% |
| 2013 Q4 | -1.44 Million AUD | -164.85% |
| 2013 Q3 | -544.8 Thousand AUD | 26.01% |
| 2012 Q4 | - AUD | 100.0% |
| 2012 Q2 | -595.04 Thousand AUD | -7.1% |
| 2012 Q1 | -555.61 Thousand AUD | 0.0% |
| 2012 FY | -2.38 Million AUD | -7.1% |
| 2012 Q3 | -595.04 Thousand AUD | 0.0% |
| 2011 Q3 | -555.61 Thousand AUD | 0.0% |
| 2011 FY | -2.22 Million AUD | 0.79% |
| 2011 Q2 | -555.61 Thousand AUD | 1.46% |
| 2011 Q1 | -563.85 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | 100.0% |
| 2010 Q2 | -563.85 Thousand AUD | -15.7% |
| 2010 Q3 | -563.85 Thousand AUD | 0.0% |
| 2010 FY | -2.24 Million AUD | -14.93% |
| 2010 Q4 | - AUD | 100.0% |
| 2010 Q1 | -487.31 Thousand AUD | 0.0% |
| 2009 Q2 | -487.31 Thousand AUD | -10.61% |
| 2009 Q3 | -487.31 Thousand AUD | 0.0% |
| 2009 Q4 | - AUD | 100.0% |
| 2009 Q1 | -440.58 Thousand AUD | 0.0% |
| 2009 FY | -1.94 Million AUD | -10.61% |
| 2008 Q3 | -440.58 Thousand AUD | 0.0% |
| 2008 Q1 | -390.87 Thousand AUD | 0.0% |
| 2008 FY | -1.76 Million AUD | -12.72% |
| 2008 Q4 | - AUD | 100.0% |
| 2008 Q2 | -440.58 Thousand AUD | -12.72% |
| 2007 FY | -1.56 Million AUD | 74.96% |
| 2007 Q4 | - AUD | 100.0% |
| 2007 Q2 | -390.87 Thousand AUD | 74.96% |
| 2007 Q1 | -1.56 Million AUD | 0.0% |
| 2007 Q3 | -390.87 Thousand AUD | 0.0% |
| 2006 FY | -6.24 Million AUD | -295.38% |
| 2006 Q2 | -1.56 Million AUD | -295.38% |
| 2006 Q3 | -1.56 Million AUD | 0.0% |
| 2006 Q1 | -394.88 Thousand AUD | 0.0% |
| 2006 Q4 | - AUD | 100.0% |
| 2005 Q3 | -394.88 Thousand AUD | 0.0% |
| 2005 Q1 | - AUD | 0.0% |
| 2005 Q4 | - AUD | 100.0% |
| 2005 Q2 | -394.88 Thousand AUD | 0.0% |
| 2005 FY | -1.57 Million AUD | 0.0% |
| 2004 Q3 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 FY | - AUD | 100.0% |
| 2004 Q1 | -736.56 Thousand AUD | 0.0% |
| 2004 Q2 | - AUD | 100.0% |
| 2003 Q4 | - AUD | 100.0% |
| 2003 Q1 | -2.29 Million AUD | 0.0% |
| 2003 Q3 | -736.56 Thousand AUD | 0.0% |
| 2003 Q2 | -736.56 Thousand AUD | 67.85% |
| 2003 FY | -2.94 Million AUD | 67.85% |
| 2002 Q1 | -350.25 Thousand AUD | 0.0% |
| 2002 Q2 | -2.29 Million AUD | -554.08% |
| 2002 FY | -9.16 Million AUD | -554.1% |
| 2002 Q3 | -2.29 Million AUD | 0.0% |
| 2002 Q4 | - AUD | 100.0% |
| 2001 Q2 | -350.25 Thousand AUD | -156.32% |
| 2001 FY | -1.4 Million AUD | -156.59% |
| 2001 Q4 | - AUD | 100.0% |
| 2001 Q3 | -350.25 Thousand AUD | 0.0% |
| 2001 Q1 | -136.64 Thousand AUD | 0.0% |
| 2000 Q1 | 509.75 AUD | 0.0% |
| 2000 Q2 | -136.64 Thousand AUD | -26906.87% |
| 2000 Q3 | -136.64 Thousand AUD | 0.0% |
| 2000 Q4 | -136.64 Thousand AUD | 0.0% |
| 2000 FY | -546 Thousand AUD | -26877.83% |
| 1999 Q3 | 509.75 AUD | 0.0% |
| 1999 FY | 2039.00 AUD | 0.0% |
| 1999 Q4 | 509.75 AUD | 0.0% |
| 1999 Q2 | 509.75 AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 227.511% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -511.925% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 75.716% |
| Biome Australia Limited | -1.67 Million AUD | -431.703% |
| Patrys Limited | -3.53 Million AUD | -150.922% |
| Orthocell Limited | -7.18 Million AUD | -23.668% |
| Imugene Limited | -149.68 Million AUD | 94.067% |
| Noxopharm Limited | -3.57 Million AUD | -148.19% |
| PYC Therapeutics Limited | -37.72 Million AUD | 76.46% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 29.125% |
| Prescient Therapeutics Limited | -8.23 Million AUD | -7.799% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | -39.276% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 8.868% |
| CSL Limited | 2.64 Billion AUD | 100.336% |
| Arovella Therapeutics Limited | -8.74 Million AUD | -1.538% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -268.612% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 124.92% |
| Starpharma Holdings Limited | -8.16 Million AUD | -8.763% |
| Nanollose Limited | -1.15 Million AUD | -667.843% |
| Memphasys Limited | -4.44 Million AUD | -99.921% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -440.898% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 2839.125% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -97.194% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 35.972% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -210.039% |
| Race Oncology Limited | -13.81 Million AUD | 35.738% |
| Nyrada Inc. | -1.38 Million AUD | -540.625% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 270.419% |
| Dimerix Limited | -17.07 Million AUD | 47.991% |
| PharmAust Limited | -9.03 Million AUD | 1.681% |
| Immutep Limited | -39.89 Million AUD | 77.741% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 79.018% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 53.562% |
| BTC Health Limited | 1.05 Million AUD | 941.526% |
| Acrux Limited | -5.8 Million AUD | -53.112% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 105.653% |
| Biotron Limited | -3.43 Million AUD | -158.416% |
| Tissue Repair Ltd | -4.13 Million AUD | -114.604% |
| AdAlta Limited | -5.38 Million AUD | -65.026% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 81.479% |
| Hexima Limited | -933.87 Thousand AUD | -850.934% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 84.859% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 49.719% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -158.413% |
| Actinogen Medical Limited | -13.04 Million AUD | 31.92% |
| Immuron Limited | -6.93 Million AUD | -28.017% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -62.068% |